GSK Quantum

GlaxoSmithKline (GSK) is advancing quantum computing applications in pharmaceutical research through partnerships with IBM's Quantum Heron and Condor processors for mRNA codon optimization and clinical data analysis, and collaboration with D-Wave for quantum annealing applications in genetic algorithms. The company worked with Capgemini UK and the National Quantum Computing Centre on quantum-enhanced drug discovery research, developing machine learning pipelines using quantum features for predicting targeted covalent drug reactivity. Led by Ross Walker, Global Director of Scientific Research Computing & Analytics, GSK participates in the QuPharm consortium alongside other major pharmaceutical companies to structure quantum computing's potential in drug discovery, focusing on optimization problems that exceed traditional computational capabilities in messenger RNA research and therapeutic development.